Skip to main content

ImmuCell Corporation

corporate_fare Company Profile

ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ICCC - Latest Insights

ICCC
Apr 24, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
ICCC
Apr 14, 2026, 4:41 PM EDT
Filing Type: PRE 14A
Importance Score:
7
ICCC
Apr 13, 2026, 7:18 PM EDT
Filing Type: 8-K
Importance Score:
7
ICCC
Apr 13, 2026, 4:38 PM EDT
Source: GlobeNewswire
Importance Score:
7
ICCC
Apr 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
ICCC
Mar 04, 2026, 4:34 PM EST
Source: Reuters
Importance Score:
7
ICCC
Feb 02, 2026, 5:22 PM EST
Filing Type: 8-K
Importance Score:
8
ICCC
Jan 08, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8